Trevena (TRVN) Competitors $0.01 0.00 (0.00%) As of 10/8/2025 03:41 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock TRVN vs. VRPX, SMFL, SCPS, ARDS, NAVB, EVLO, GNCAQ, GNCA, STAB, and AMPEShould you be buying Trevena stock or one of its competitors? The main competitors of Trevena include Virpax Pharmaceuticals (VRPX), Smart for Life (SMFL), Scopus BioPharma (SCPS), Aridis Pharmaceuticals (ARDS), Navidea Biopharmaceuticals (NAVB), Evelo Biosciences (EVLO), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Statera Biopharma (STAB), and Ampio Pharmaceuticals (AMPE). These companies are all part of the "pharmaceutical products" industry. Trevena vs. Its Competitors Virpax Pharmaceuticals Smart for Life Scopus BioPharma Aridis Pharmaceuticals Navidea Biopharmaceuticals Evelo Biosciences Genocea Biosciences Genocea Biosciences Statera Biopharma Ampio Pharmaceuticals Virpax Pharmaceuticals (NASDAQ:VRPX) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation. Do institutionals and insiders believe in VRPX or TRVN? 32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.6% of Trevena shares are owned by institutional investors. 3.7% of Virpax Pharmaceuticals shares are owned by insiders. Comparatively, 2.7% of Trevena shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has higher valuation and earnings, VRPX or TRVN? Virpax Pharmaceuticals has higher earnings, but lower revenue than Trevena. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirpax PharmaceuticalsN/AN/A-$15.19MN/AN/ATrevena$443K0.03-$40.29M-$47.040.00 Do analysts rate VRPX or TRVN? Trevena has a consensus target price of $5.00, indicating a potential upside of 41,566.67%. Given Trevena's stronger consensus rating and higher probable upside, analysts clearly believe Trevena is more favorable than Virpax Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virpax Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Trevena 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to VRPX or TRVN? In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score. Company Overall Sentiment Virpax Pharmaceuticals Neutral Trevena Neutral Which has more risk and volatility, VRPX or TRVN? Virpax Pharmaceuticals has a beta of 1.96, suggesting that its stock price is 96% more volatile than the S&P 500. Comparatively, Trevena has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Is VRPX or TRVN more profitable? Trevena's return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Virpax PharmaceuticalsN/A -1,554.34% -338.29% Trevena N/A N/A -119.55% SummaryTrevena beats Virpax Pharmaceuticals on 5 of the 9 factors compared between the two stocks. Get Trevena News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart TRVN vs. The Competition Export to ExcelMetricTrevenaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$12K$1.05B$6.09B$10.54BDividend YieldN/A4.84%5.69%4.71%P/E Ratio0.001.2885.5627.61Price / Sales0.03151.38535.65201.06Price / CashN/A17.6437.9261.55Price / Book0.007.5213.036.76Net Income-$40.29M-$7.77M$3.30B$275.88M7 Day PerformanceN/A26.65%4.35%2.81%1 Month PerformanceN/A27.91%9.50%9.24%1 Year PerformanceN/A-5.66%85.16%35.42% Trevena Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRVNTrevena2.0141 of 5 stars$0.01flat$5.00+41,566.7%-99.2%$12K$443K0.0040VRPXVirpax Pharmaceuticals0.061 of 5 stars$0.04+39.8%N/A-99.8%$44KN/A0.007Gap UpSMFLSmart for LifeN/A$0.01-16.7%N/A-92.6%$35K$11.11M0.00110Gap UpSCPSScopus BioPharmaN/A$0.00flatN/AN/A$13KN/A0.009Gap UpARDSAridis PharmaceuticalsN/A$0.00-88.2%N/AN/A$11KN/A0.0030NAVBNavidea BiopharmaceuticalsN/A$0.00-50.0%N/AN/A$10K$8.13K0.0010News CoverageEVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070STABStatera BiopharmaN/A$0.00flatN/A-50.0%$5KN/A0.0020AMPEAmpio PharmaceuticalsN/A$0.00flatN/A+22.7%$3KN/A0.0020 Related Companies and Tools Related Companies VRPX Alternatives SMFL Alternatives SCPS Alternatives ARDS Alternatives NAVB Alternatives EVLO Alternatives GNCAQ Alternatives GNCA Alternatives STAB Alternatives AMPE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRVN) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevena, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevena With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
